GLP-1 Medicines: Australian Regulation & Safety Information
Short answer: GLP-1 medicines has ARTG-registered products in Australia. Only TGA-approved registered products are available on prescription. These use standard prescriptions.
General information only. These sources support educational and regulatory context and do not endorse or promote any medicine.
Australian regulatory status
GLP-1 medicines has ARTG-registered products in Australia. Only TGA-approved registered products are available on prescription. These use standard prescriptions.
Registration and exceptional access are different
ARTG registration applies to a specific product and its approved indications. An eligible unapproved medicine may instead require a TGA application and approval before supply, or Authorised Prescriber authorisation. Neither pathway is an endorsement, a finding of suitability for everyone, or an override of supply prohibitions.
Compounding restrictions
Compounded GLP-1 medicines cannot be legally supplied in Australia since 1 October 2024. The prohibition is not removed by a prescription or a TGA application.
Evidence and uncertainty
Laboratory and animal findings cannot establish patient outcomes. Small or early studies may not identify uncommon harms, interactions or long-term risks. Research on one formulation or population cannot automatically be applied to another. This page does not rank treatments or recommend a medicine.
Safety questions for an individual assessment
A registered doctor considers symptoms, medical history, current medicines, allergies and any necessary investigations. Pregnancy, breastfeeding, cancer history and other health conditions may change the assessment. Potential interactions and the limits of available evidence need to be discussed. Do not start, combine or adjust medicines based on online information.
Unregulated products and importation
A research-only label does not establish quality or lawful therapeutic supply. Identity, concentration and sterility may be unverified. Personal importation has conditions and restrictions; check the official TGA guidance rather than relying on a seller's claims. A prescription is not an automatic exemption from every restriction.
Clinical decisions and follow-up
Whether any treatment is appropriate is a decision for a registered doctor after an individual assessment. Monitoring and follow-up depend on the person and the product; there is no universal timetable or promised outcome. Questions about symptoms or suspected adverse effects should be directed to a health practitioner. In an emergency, call 000.
FAQs
- Does this page recommend a treatment?
- No. It provides educational regulatory and safety information only, not medical advice or a recommendation.
- Does special access mean a medicine is approved?
- No. Exceptional access to an eligible unapproved medicine is distinct from ARTG registration.
- Can an online listing establish that a product is safe?
- No. A product listing, research label or anecdote does not establish quality, safety or lawful supply.
Sources
- Prescription medicines — Therapeutic Goods Administration (TGA) — Australian Government
- Australian Register of Therapeutic Goods (ARTG) — Therapeutic Goods Administration (TGA) — Australian Government
- Tirzepatide Once Weekly for the Treatment of Obesity — Jastreboff AM et al. — N Engl J Med — 2022 (Registered-medicine clinical trial)DOI
- Once-Weekly Semaglutide in Adults with Overweight or Obesity — Wilding JPH et al. — N Engl J Med — 2021 (Registered-medicine clinical trial)DOI
Sources provide regulatory and educational context only and do not endorse any medicine or this site. See all sources
Related articles
Written by the Peptide Doctor Australia editorial team — last updated 29 May 2026.
General information only, not medical advice. Whether any treatment is appropriate is a decision for a registered doctor after an individual assessment.
Questions about whether any treatment is right for you should be discussed with a registered doctor. How consultations work.